Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Jack Henneman
AddedMar 31, 2024
UpdatedMay 1, 2026
Jack Henneman

Jack Henneman

Board Member, Aprea Therapeutics

Jack Henneman's Career

Aprea Therapeutics
Aprea Therapeutics

Boston, MA, US

Board Member· Board
Anika Therapeutics
Anika Therapeutics

Bedford, MA, US

Board Member· Board
Orthofix
Orthofix

Lewisville, TX, US

Board Member· Board
R1 Rcm
R1 Rcm

Chicago, IL, US

Board Member· Board
Alafair Biosciences
Alafair Biosciences

Austin, TX, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Jack Henneman's Career

Aprea Therapeutics
Aprea Therapeutics
Acquired02019Boston, MA, US
Board Member· Board

Leadership at Aprea Therapeutics

Bernd SeizingerBernd SeizingerBoard Member
Oren GiladOren GiladFounder
Chris SchadeChris SchadeBoard Member

Similar to Aprea Therapeutics

ApoGen BiotechnologiesApoGen BiotechnologiesSeattle, WA, USTherapeuticsest. 2014ApoGen BiotechnologiesSeattle, WA, US · est. 2014

ApoGen Biotechnologies, Inc.: Innovating new class of therapeutics in biotechnology.

Series A · $11M7
Apexian PharmaceuticalsApexian PharmaceuticalsIndianapolis, IN, USDrugs, Pharmaceuticalsest. 2005Apexian PharmaceuticalsIndianapolis, IN, US · est. 2005

Apex Therapeutics, based in Indianapolis, US, develops and markets drugs for cancer and eye diseases.

Angel · $6.9M5
Atossa TherapeuticsAtossa TherapeuticsSeattle, WA, USTherapeuticsest. 2009Atossa TherapeuticsSeattle, WA, US · est. 2009

Seattle-based Atossa Therapeutics, Inc. pioneers in discovering unique therapeutics for breast cancer globally.

Public · $57.8M75
Parthenon TherapeuticsParthenon TherapeuticsCambridge, MA, USCancer Therapiesest. 2019Parthenon TherapeuticsCambridge, MA, US · est. 2019

Parthenon Therapeutics develops innovative anti-cancer therapies, reprogramming the tumor microenvironment.

Series A · $65M43
Anika Therapeutics
Anika Therapeutics
Public3451992Bedford, MA, US
Board Member· Board

Leadership at Anika Therapeutics

Raymond LandRaymond LandBoard Member
Joseph BowerJoseph BowerBoard Member
Susan VogtSusan VogtBoard Member
Glenn LarsenGlenn LarsenBoard Member
Cheryl Renee BlanchardCheryl Renee BlanchardBoard Member
Jeff ThompsonJeff ThompsonBoard Member

Similar to Anika Therapeutics

Ankasa Regenerative TherapeuticsAnkasa Regenerative TherapeuticsLos Angeles, CA, USStem Cell Therapiesest. 2014Ankasa Regenerative TherapeuticsLos Angeles, CA, US · est. 2014

Ankasa Therapeutics: Advancing regenerative medicine through stem cell technology for improved tissue healing.

Series A · $14.5M3k
Acorda TherapeuticsAcorda TherapeuticsArdsley, NY, USBiotechnologyest. 1995Acorda TherapeuticsArdsley, NY, US · est. 1995

Acorda Therapeutics Inc.: Biotech firm innovating therapies for neurological conditions and spinal repair.

Public · $151.6M344
AmplicoreAmplicoreMason, OH, USPharmaceuticals, Therapeuticsest. 2019AmplicoreMason, OH, US · est. 2019

Amplicore develops regenerative injectable therapeutics for musculoskeletal disorders.

Seed · $4M8
BioventusBioventusDurham, NC, USMedical Devices, Orthobiologicsest. 2012BioventusDurham, NC, US · est. 2012

Bioventus Inc.: Global leader in orthobiologics, offering advanced medical devices and treatments worldwide.

Public · $427M1.1k
Orthofix
Orthofix
Public1.1k1980Lewisville, TX, US
Board Member· Board

Leadership at Orthofix

Guy JordanGuy JordanBoard Member
Jon SerbousekJon SerbousekCEO
Mike PaolucciMike PaolucciBoard Member
Stuart EssigStuart EssigBoard Member
Giovanni De BastianiGiovanni De BastianiFounder
Cathy BurzikCathy BurzikBoard Member
R1 Rcm
R1 Rcm
Public$200M27.8k2003Chicago, IL, US
Board Member· Board

Leadership at R1 Rcm

Mary TolanMary TolanCo-Founder
Michael ClineMichael ClineCo-Founder
Neal MoszkowskiNeal MoszkowskiBoard Member
Etienne DeffargesEtienne DeffargesBoard Member
Brian DeanBrian DeanBoard Member
Anthony R TersigniAnthony R TersigniBoard Member
Alafair Biosciences
Alafair Biosciences
Series B$13.8M222011Austin, TX, US
Board Member· Board

Leadership at Alafair Biosciences

John JoyoprayitnoJohn JoyoprayitnoCo-Founder & CEO
Sarah MayesSarah MayesCo-Founder
Mark BenedykMark BenedykBoard Member

Jack Henneman's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Jack Henneman

RJ MillerRJ MillerCo-Founder · LumateBharat DaveBharat DaveBoard Member · AlphionPete LeddyPete LeddyBoard Member · Pathway GenomicsDavid ChaoDavid ChaoBoard Member · 51jobMohammad AzabMohammad AzabBoard Member · DurectDoug WardDoug WardBoard Member · Personal Genome Diagnostics